drugset / Trial / NCT01020526

Pregabalin In Adolescent Patients With Fibromyalgia

NCT01020526

Phase 4 Completed 63 enrolled Viatris Inc.
Non-randomizedOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the long-term safety of pregabalin in adolescent patients who participated in the previous fibromyalgia study (A0081180) and who wish to recieve open-label pregabalin

Timeline

Start
2010-09
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 75 mg Oral
Subject Pregabalin Small molecule 450 mg Oral

Indications